Commentary|Podcasts|November 13, 2025

Improving Site Satisfaction Through Better Technology and Collaboration

Melissa Hutchens, vice president of research & benchmarking at WCG, and Jimmy Garza, senior director of clinical operations at Bayer, discuss findings from the latest WCG CenterWatch Global Site Relationship Survey, revealing a decline in overall site satisfaction. They explore key drivers behind this trend, including technology usability, communication gaps, and limited site input in protocol design, and share actionable approaches to strengthen sponsor-site partnerships and improve study execution.

Melissa Hutchens, vice president of research & benchmarking at WCG, and Jimmy Garza, senior director of clinical operations at Bayer, discuss:

Key findings from the 2025 WCG CenterWatch Global Site Relationship Survey and what’s driving the decline in site satisfaction

How sponsors can leverage technology to enhance, not hinder, site efficiency and usability
Strategies to incorporate site feedback earlier in protocol design and planning
Practical ways to strengthen communication, support study coordinators, and improve overall sponsor-site collaboration
And more!

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

© photon_photo - © photon_photo - stock.adobe.com

October 22nd, 2026

Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology

Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.

© putilov_denis - © putilov_denis - stock.adobe.com

October 28th, 2026

Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without

The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.

October 27th, 2026

Closing the Medical Writing Capacity Gap: Why Training Beats Technology

Medical writing capacity pressure is fundamentally a talent development problem, not a technology problem, since hybrid resourcing and AI cannot substitute for the experienced judgment needed to review AI output and mentor the next generation of writers.

October 21st, 2026

Obesity Is More Than Weight: Practical Approaches to Managing Comorbidities in Clinical Research

Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.

October 21st, 2026

What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight

In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.

October 15th, 2026

The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution

In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.

October 29th, 2026

ACT Brief: Community Trial Access Technology, RBQM Infrastructure, and Digital Clone Use Cases

In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.

October 28th, 2026

What It Would Take to Make Community Trials Accessible and Scalable

In this video interview, Kent Thoelke, CEO of Paradigm Health, outlines why anti-kickback guidance and modern EHR-integrated trial matching technology must work in tandem to reach representative patient populations at the community level.